DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Gregory Renza - 2 Oppenheimer - 2 Jeff Jones - 2 Piper Sandler - 2 Edward Tenthoff - 2 Eli Lilly - 2 Dan Lyons - 2 Janus Henderson - 2
Top related locs:
Mariana Bristol Biopharma radiopharma New Jersey Shanghai China Europe
Top related orgs:
AstraZeneca - 6 Fusion Pharmaceuticals - 3 pharma - 2 RBC Capital Markets - 2 TRT - 2 Novartis - 2 Mariana Oncology - 2 Janus - 2

Search resuls for: "Fusion Pharmaceuticals"


6 mentions found


☆ This up-and-coming cancer treatment could be a $25 billion market opportunity — it's already a hotbed for M&A
  + stars: | 2024-05-23 | by ( Michelle Fox | ) www.cnbc.com   time to read: +7 min
RBC Capital Markets sees a $25 billion market opportunity for the space. The average analyst rating is hold, with 8% upside to the average analyst price target, according to FactSet. Eli Lilly has an average analyst rating of overweight and 8.3% upside to the average analyst price target, according to FactSet. Stock Chart Icon Stock chart icon AstraZeneca's one-year performanceAstraZeneca shares have an average analyst rating of overweight and nearly 6% upside to the average analyst price target, according to FactSet. Stock Chart Icon Stock chart icon Bristol-Myers Squibb's one-year performance
Persons: It's, Gregory Renza, Renza, Oppenheimer, Jeff Jones, Piper Sandler, Edward Tenthoff, Eli Lilly, Dan Lyons, Janus Henderson, Myers Squibb, William Blair, Matt Phipps, Jefferies, Andrew Tsai, They've, Janus Henderson's Lyons, Jones, Piper Sandler's Tenthoff, Myers Organizations: pharma, RBC Capital Markets, TRT, Novartis, Mariana Oncology, Janus, Janus Henderson Investors, Bristol, RayzeBio, Karuna Therapeutics, AstraZeneca, Fusion Pharmaceuticals, GlobalData's Pharma Intelligence, Pluvicto Locations: Mariana, Bristol
☆ A corner of the cancer therapy market is heating up—Here are the names investors need to know
  + stars: | 2024-05-23 | by ( Michelle Fox | ) www.cnbc.com   time to read: +8 min
A $25 billion market Meanwhile, RBC Capital Markets sees a $25 billion market opportunity for the space. A name Jones likes is Perspective Therapeutics , which he rates outperform. CATX 1Y mountain Perspective Therapeutics year to date Cantor Fitzgerald is also bullish on the name. So it's really an ideal profile," said Piper Sandler analyst Edward Tenthoff, who doesn't cover Perspective Therapeutics. Then there is Lantheus Holdings , which calls itself a radiopharmaceutical-focused company and has a $5.6 billion market cap.
Persons: There's, Eli Lilly, Myers, Jefferies, Andrew Tsai, radiopharma, Oppenheimer, Jeff Jones, FactSet, William Blair, Read, — it's, Andy Hsieh, Gregory Renza, Jones, Cantor Fitzgerald, Louise Chen, it's, Piper Sandler, Edward Tenthoff, Dan Lyons, Janus Henderson, Lantheus, Roanna Ruiz Organizations: Novartis, pharma, Mariana Oncology, Myers Squibb, AstraZeneca, Fusion Pharmaceuticals, RBC Capital Markets, TRT, Therapeutics, Alpha, Janus, Janus Henderson Investors, Lantheus Holdings, Lantheus, Leerink, ~$ Locations: Biopharma, Bristol, Mariana, radiopharma, New Jersey
☆ AstraZeneca targets $80 billion in total revenue by 2030 in 'post-Covid era'
  + stars: | 2024-05-21 | by ( Sophie Kiderlin | In | ) www.cnbc.com   time to read: +2 min
Costfoto | Future Publishing | Getty ImagesLONDON — Pharmaceutical company AstraZeneca on Tuesday said it planned to increase its total revenue to $80 billion by 2030 — up 75% from $45.8 billion in 2023. AstraZeneca will focus on its oncology, biopharmaceuticals and rare diseases businesses and expects to release an additional 20 medicines in the next six years. "Many of them have the potential to be $5 billion drugs," Sarin noted. A company statement detailed that this revenue figure could be hit annually for many of the new medicines in peak years. "For the entire market to get replaced it will take time, but we think we have the technology today to start replacing them," Sarin told CNBC.
Persons: CNBC's Arabile Gumede Organizations: Astrazeneca, Artificial Intelligence, — Pharmaceutical, AstraZeneca, CNBC, U.S . FDA, Pharmaceuticals, Investments Locations: Shanghai, China, Europe, London, Singapore
☆ AstraZeneca to withdraw Covid vaccine worldwide, citing a drop in demand
  + stars: | 2024-05-08 | by ( Sophie Kiderlin | In | ) www.cnbc.com   time to read: +2 min
In this photo illustration a covid-19 vaccine is seen with the AstraZeneca logo in the background. (Photo Illustration by Nikos Pekiaridis/NurPhoto via Getty Images)Pharmaceutical giant AstraZeneca on Wednesday said it planned to withdraw its Covid-19 vaccine as demand for it has declined. Demand for the Vaxzevria vaccine has tailed off as new vaccines tailored to specific Covid variants have emerged, AstraZeneca said in a statement. "As multiple, variant COVID-19 vaccines have since been developed there is a surplus of available updated vaccines. Next to Covid vaccines, AstraZeneca has been working on a range of other treatments for illnesses including cancer.
Persons: Nikos Pekiaridis Organizations: AstraZeneca, Getty Images, Pharmaceutical, University of Oxford, Covid, World Health Organization, European Union, Fusion Pharmaceuticals Inc Locations: U.K
☆ AstraZeneca bets on new cancer treatments with $2 billion Fusion Pharma purchase
  + stars: | 2024-03-19 | by ( ) www.cnbc.com   time to read: +2 min
AstraZeneca said on Tuesday it will buy clinical-stage biopharmaceutical company Fusion Pharmaceuticals Inc for about $2 billion in cash as the Anglo-Swedish drugmaker bets on next-generation cancer treatments. The drugmaker will pay $21 per Fusion share, a premium of more than 97% to the U.S.-listed company's closing price on Monday. Fusion is developing "next-generation" radioconjugates (RCs) to treat cancer. RCs deliver a radioactive isotope directly to cancer cells through precise targeting using molecules and have emerged as a promising modality in cancer treatment over recent years, AstraZeneca said. Radiotherapy and chemotherapy have been the mainstays of cancer treatment for decades.
Persons: AstraZeneca, Susan Galbraith Organizations: Fusion Pharmaceuticals Inc, Amolyt Pharma, AstraZeneca, Fusion, Oncology, U.S . Food, Drug Administration, FDA Locations: Swedish, U.S, radioconjugates
☆ AstraZeneca: Fusion acquisition will be a cost effective-investment that can improve cancer outcomes
  + stars: | 2024-03-19 | by ( ) www.cnbc.com   time to read: 1 min
Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailAstraZeneca: Fusion acquisition will be a cost effective-investment that can improve cancer outcomesDr. Susan Galbraith, executive vice-president of oncology and R&D at AstraZeneca, discusses the healthcare giant's $2.4bn acquisition of Fusion Pharmaceuticals.
Persons: Susan Galbraith Organizations: AstraZeneca, Fusion, Fusion Pharmaceuticals
0 next >>
Total: 6